Skip to main content
Premium Trial:

Request an Annual Quote

Miraculins to Validate Colorectal Biomarkers with Fox Chase Cancer Center

NEW YORK, June 13 (GenomeWeb News) - Miraculins, a cancer biomarker discovery firm, said today that it will collaborate with FoxChaseCancerCenter to validate markers in a colorectal cancer diagnostic project.


Miraculins picked up the biomarkers in its acquisition of Europroteome's IP portfolio last June.


Under the terms of the agreement, FoxChaseCancerCenter will provide a "significant number" of biological samples, which Miraculins will process with its BEST platform, which combines proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.


The company said that its test has sensitivity and specificity of more than 80 percent.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.